A groundbreaking study, conducted by a team of international researchers, has challenged long-held scientific assumptions about how giant trees manage…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
The Unapproved QUAD Cocktail: A Closer Look at its Composition QUAD is a compounded sublingual dose product marketed by MEDVi…
Read More
The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed ‘fastest growing company in history.’
The narrative of MEDVi, an AI-powered telehealth startup, recently unfolded with a stark duality: hailed by The New York Times…
Read More
The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed ‘fastest growing company in history.’
A burgeoning telehealth startup, MEDVi, heralded by The New York Times as a prime example of an AI-powered venture reaching…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
In the wake of The New York Times’ April 2 profile, which painted MEDVi CEO Matthew Gallagher as a "vibe-coded…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
QUAD is marketed by MEDVi as a sublingual, four-drug cocktail for erectile dysfunction, combining three well-known PDE5 inhibitors—sildenafil, tadalafil, and…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
The digital health company MEDVi, recently spotlighted in an April 2 New York Times profile that depicted CEO Matthew Gallagher…
Read More
Long-Term Residential Exposure to Chlorpyrifos Increases Parkinson’s Disease Risk by Over Two and a Half Times UCLA Health Study Finds
A groundbreaking longitudinal study conducted by researchers at UCLA Health has established a definitive link between chronic residential exposure to…
Read More
